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ABSTRACT 
 
Aim The increased relevance of liver surgery and transplantation as a therapeutic modality 
over the last two decades mandates the development of novel strategies to improve liver re-
generation. Here we studied whether erythropoietin (EPO) improves liver regeneration after 
hepatectomy in pigs.  
Methods Eighteen female pigs underwent laparoscopic left lateral liver resection and were 
allocated randomly into three groups. No EPO was administered to the control group (group 
1, n=6). Group 2 (n=6) received EPO topically to the liver resection surface in a fibrin sealant. 
Group 3 (n=6) received EPO topically and systemically. Pigs were sacrificed 14 days after 
hepatectomy. The fraction of proliferating hepatocytes was determined by ki-67 immu-
nostaining. Liver volume was determined by the principle of Archimedes,  
Results Liver weight and volume were significantly increased in group 3 (1249  ± 223 g, 
1073 ± 190 ml) compared to group 2 (1027 ± 167 g, 894 ± 105 ml) and group 1 (923 ± 186 g, 
813 ± 165 ml). Ki-67 immunostaining of liver tissue close to the resection surface demon-
strated a significantly increased percentage of proliferating hepatocytes in group 3 (4.3 ± 1.96 
%) and in group 2 (3.5% ± 0.98 %) as compared to group 1 (1.15 ± 1.2 %) 14 days after 
hepatectomy.  
Conclusions Our results indicate for the first time that EPO supports liver regeneration after 
hepatectomy. 
 
Keywords: erythropoietin, hepatocytes, laparoscopic hepatectomy, regeneration 
Abbreviations: EPO: erythropoietin, i.v.: intravenous, i.m.: intramuscular, PH: partial 
hepatectomy, Hb: haemoglobin, SD: standard deviation, PCNA: Proliferating Nuclear Anti-
gen, d: day, OP: operation 
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INTRODUCTION 
 
The remarkable proliferative capacity of 
the liver is vividly captured in the Greek 
myth of Prometheus(Lee, 2001; Bucher, 
1991). Nevertheless, the exquisite regenera-
tive capacity of the liver is finite and often 
insufficient to combat many liver diseases 
(Cataldegirmen et al., 2005). For example, 
hepatic failure occurring after liver resec-
tion, a complication dreaded by surgeons, is 
associated with a poor prognosis (Mullin et 
al., 2005). The maximum extent of hepatic 
resection compatible with a safe postopera-
tive outcome is difficult to determine and 
depends on many factors including residual 
liver function (Yigitler et al., 2003). Despite 
widespread interest in the molecular mecha-
nisms underlying liver regeneration 
(Michalopoulos and DeFrances, 1997, 
2005), the clinically relevant limits of the 
ability of the liver to regenerate are not well 
understood. Presently, no efficient therapy 
is available to enhance regeneration and 
optimize survival when the residual liver is 
excessively small. On the other hand, the 
growth of liver surgery and transplantation 
as a therapeutic modality over the last two 
decades mandates the development of novel 
strategies to improve liver regeneration and 
optimize outcomes (Cataldegirmen et al., 
2005).  
Experimental evidence supports a role 
for erythropoietin (EPO) in the repair and 
regeneration also of non-hematpoietic or-
gans (Sasaki, 2003). Recent studies have 
identified multiple paracrine and autocrine 
functions of EPO. These functions coordi-
nate local responses to injury by maintain-
ing vascular autoregulation and attenuating 
both primary (apoptotic) and secondary 
(inflammatory) causes of cell death. EPO 
has been shown to prevent apoptosis and to 
stimulate mitosis and signalling in astro-
cytes (Sugawa et al., 2002), endothelial 
cells (Jaquet et al., 2002), and cardio-
myoblasts (Ogilvie et al., 2000) maintained 
in vitro. Although it is well known that 
EPO plays an important role in myocardial 
and cerebral regeneration, the role of EPO 
in liver regeneration is unknown. Shino-
zuka et al. (2000) conclude in their trial that 
the simultaneously preoperative administra-
tion of autologous blood and EPO, mark-
edly reduced the requirement for homolo-
gous blood transfusion during the surgery 
and reduced postoperative complications. 
In the present study we studied the in-
fluence of EPO on liver regeneration using 
a laparoscopic porcine liver resection 
model. We report for the first time that EPO 
improves liver regeneration after topical 
administration to the resection surface in a 
fibrin sealant and even the more after com-
bined topical and systemic administration. 
 
MATERIALS AND METHODS 
 
Experimental design and operative proce-
dure 
Eighteen commercially available, fe-
male German Landrace pigs (Lehr- und 
Versuchsgut, Oberholz, Leipzig, Germany) 
were allocated randomly into three groups 
and studied with the approval of the local 
Institutional Animal Use Committee 
(Regierungspräsidium, Leipzig, Germany). 
Animals were fed twice daily at 7 a. m. and 
3 p. m. with standard pig diet (ATR Starter 
Extra 13.0, ATR Landhandel, Ratzeburg, 
Germany). The animals were housed in an 
animal resource facility at the Center for 
Experimental Medicine (Medizinisch Ex-
perimentelles Zentrum, University of Leip-
zig, Germany). Pigs underwent laparo-
scopic left hemihepatectomy and were ob-
served postoperatively for two weeks. The 
operation was performed using CUSA 
(CUSA; Valleylab Boulder, CO, USA) and 
Ultracision (UltraCision, Ethicon). The pigs 
were placed in the supine position and six 
12 mm laparoscopic port sheets were in-
serted through the anterior abdominal wall. 
Surgical procedures were performed with-
out the Pringle manoeuvre (Pringle, 1908). 
The weight of the resectate was similar in 
all groups. No EPO was administered to the 
control group (n=6). In group 2 (n=6) 
10,000 units of EPO (ERYPO, Epoetin alfa, 
ORTHO BIOTECH, Division of Janssen-
Cilag GmbH, Neuss, Germany) were mixed 
with 2 ml of fibrin sealant (Quixil, Omrix, 
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Rhode-St-Genèse, Belgium). The mixture 
was applied topically to the liver resection 
surface (Carless et al., 2002). The same 
procedure was conducted with group 3 
(n=6). In addition to the topical EPO treat-
ment all pigs in group 3 received 10,000 
units of EPO systemically (i. v.) on days 0, 
3, 7, and 11. The pigs were sacrificed on 
day 14.  
 
Medication 
Pre- and postoperative medication, ex-
posure to anesthesia, and postoperative care 
were identical for all animals. After pre-
medication with azaperone (5 mg·kg-1, 
i. m.) and atropine (0.05 mg·kg-1, i. m.), 
anaesthesia was performed using thiopental 
(10 mg·kg-1, i. v.) and fentanyl (5 µg·kg-1, 
i. v.). Muscle relaxation was induced with 
pancuronium bromide. Postoperative anal-
gesia was provided by metamizole and piri-
tramide. Prior to taking blood samples the 
animals were sedated by i. m. administra-
tion of a mixture of azaperone (15 mg·kg-1 
body weight, Stresnil, Janssen–Cilag 
GmbH, Germany), ketamine hydrochloride 
(10 mg·kg-1 body weight, ketamine, Sanofi-
Cefa GmbH, Germany) and atropine sulfate 
(0.05 mg·kg-1body weight, Atropin, B. 
Braun Melsungen, Germany). 
 
Sample collection 
Liver biopsies were taken during the 
first operation (day 0). The pigs underwent 
a second laparoscopic intervention 24 hrs 
later (day one). During this procedure, ap-
proximately 5 ml of liver tissue were taken 
from 1 cm beneath the resection surface in 
order to avoid necrotic tissue from the op-
eration. On day 14 another specimen was 
taken from beneath the resection surface. 
Additionally bone marrow from the femur 
was examined on day 14 (Fig. 1). The vol-
ume of the resectate and the volume of the 
residual liver on day 1 and day 14, respec-
tively, were measured according to the 
principle of Archimedes (F(A) = p * V * g). 
Blood samples were taken immediately 
before surgery, after wound closure, three 
hours after the operation, after 24 hours, on 
day 3, on day 7 and on day 14. 
 
Immunohistochemical analysis 
Along with conventional hematoxylin-
eosin (HE) stains for all tissues examined, 
immunohistochemistry was performed as 
described previously (Tannapfel et al., 
2003). The bone marrow was stained with 
CD117 antibody (polyclonal rabbit, c-kit, 
DAKO, Copenhagen, Denmark, 1:250) and 
counterstained with hematoxylin. The posi-
tive cells were counted and the relation be-
day 0 Pre- 
operative 
3h  
first OP
6h 
Post-operative
24h 
2nd OP 
3d 7d 
 
Blood samples 
Liver 
biopsy 
Blood sample 
14d 
 
Liver- 
 biopsy 
Bone  
marrow  
biopsy 
Liver 
biopsy 
Figure 1: Schedule for operations (OP) and biopsies 
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tween erythropoiesis and myelopoiesis was 
examined. Immunohistochemical staining 
for Ki-67 [MIB-1] and PCNA [Proliferating 
Cell Nuclear Antigen] was performed to 
assess the proliferative activity of the liver 
specimens at various time points. The tis-
sues were excised at designated time points 
after partial hepatectomy, fixed in 4 % buff-
ered formaline solution and embedded in 
paraffin wax. For immunohistochemistry 
3 µm thick sections of formaline fixed par-
affin embedded tumor tissue were mounted 
on poly-L-lysine capillary slides, dried for 
20 minutes at 70 °C, dehydrated through 
graded alcohol and cleared in xylene. For 
detection, we used the streptavidin-biotin 
immunoperoxidase technique using a LAB 
kit (DAKO, Copenhagen, Denmark). A 
counterstaining with hematoxylin was used 
to visualize the nuclei in the tissue sections. 
The number of Ki-67 and PCNA positive 
hepatocyte nuclei was determined and ex-
pressed as a percentage of all hepatocytes. 
Only cells with normal hepatocyte mor-
phology were counted. Each tissue sample 
was examined and counted by two patholo-
gists blinded for any experimental informa-
tion (AT, EH). 
 
Statistical analysis 
The results were expressed as the mean 
± SD. The statistical significance of differ-
ences between sample means was assessed 
with Kruskal-Wallis One Way Analysis of 
Variance on Rank test and Mann-Whitney 
Rank Sum Test (SigmaStat). Differences 
were considered significant at p < 0.05. 
Statistics were compiled in cooperation 
with the Institute for Medical Informatics, 
Statistics and Epidemiology, University of 
Leipzig. 
 
RESULTS 
 
EPO accelerates liver weight gain after 
resection 
Eighteen pigs underwent successful 
laparoscopic left liver resection. Mean body 
weight (± standard deviation) of the pigs 
prior to operation was 48 ± 4.42, 53 ± 6.76 
and 51 ± 9.80 kg in groups 1, 2 and 3, re-
spectively. The mean weight of the resected 
tissue in groups 1-3 was 183 ± 69, 205 ± 49 
and 206 ± 88 g, respectively.  
Interestingly, combined systemic and 
topical administration of EPO (group 3) 
significantly accelerated liver weight gain 
by 26 % compared to the controls (group 1) 
(p=0.039). Fourteen days after surgery 
mean liver weight was 1249 ± 222.5 g in 
group 3 compared to only 923 ± 186 g in 
the controls (Fig. 2).  
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Figure 2: Liver weight 14 days after partial left 
sided hepatectomy. Systemic administration of 
EPO produced a 26 % increase of liver weight 
compared to the control group (p=0.039*).  
 
Topical administration of EPO alone 
(group 2) did not cause a significant in-
crease in liver weight. Nevertheless, mean 
liver weight in group 2 was 1027 ± 167 g 
that was 10.1 % more compared to the con-
trols. A similar result as for liver weight 
was obtained for liver volume. Fourteen 
days after surgery mean liver volumes were 
813.4 ± 164.6, 894.0 ± 104.7 and 1073 ± 
190.1 ml for groups 1-3, respectively. Thus, 
combined systemic and topical administra-
tion of EPO (group 3) led to a 31.9 % in-
crease in liver volume over the control 
group (p=0.043) (Fig. 3). 
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Figure 3: Liver volume 14 days after partial left 
sided hepatectomy. Systemic administration of 
EPO produced a 24.2 % increase in liver vol-
ume compared to the control group (p=0.043*).  
 
EPO mediated liver weight gain is associ-
ated with increased hepatocyte prolifera-
tion 
Hepatocyte proliferation was quantified 
by determination of the percentage of Ki-67 
positive hepatocyte nuclei before as well as 
1 and 14 days after liver resection. The ex-
pression of Ki-67 was not significantly dif-
ferent between day 0 and day 1 (Fig. 4A). 
Additionally, no relevant difference was 
seen between pigs treated with EPO 
(groups 2 and 3) and the controls (group 1). 
However, a clear influence of EPO was 
observed on day 14 after surgery. The mean 
percentage of Ki-67 positive nuclei was 
1.52 ± 1.17, 3.50 ± 0.98 and 4.30 ± 1.96 % 
in groups 1, 2 and 3, respectively (Fig. 4A 
and 4B). Thus, topical administration of 
EPO alone (group 2) caused a 2.3-fold in-
crease in Ki-67 positive nuclei (p=0.0176), 
whereas combined topical and systemic 
administration of EPO (group 3) led to a 
2.8-fold increase (p=0.0173). In conclusion, 
both, topical as well as combined systemic 
and topical administration of EPO, caused a 
clear increase in proliferation of hepato-
cytes close to the resection surface 14 days 
after surgery. The percentage of PCNA 
positive nuclei to total nuclei was increased 
in groups 2 and 3 as compared to group 1, 
but the difference did not reach statistical 
significance. In groups 1-3 the percentage 
of PCNA positive nuclei was 25.8 ± 8.1, 
29.9 ± 7.2 and 37.2 ± 14.3, respectively.  
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Figure 4.A: Effect of EPO on proliferation of 
hepatocytes as evidenced by expression of Ki-
67. Biopsies were taken 1 cm beneath the re-
section surface on the day of liver resection, 
24 h later and on day 14. Topical and systemic 
administration of EPO led to a significant in-
crease in hepatocytes with Ki-67 positive nuclei 
14 days after liver resection compared to 
group 1 (p= 0.0176*, p= 0.0173*). 
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A. 
 
B. 
 
C. 
 
Figure 4.B: Ki-67 immunostaining of liver slices 
14 days after liver resection. Ki-67 positive nu-
clei are stained reddish-brown. Photos A, B and 
C show representative results from groups 1, 2 
and 3, respectively. Magnification: x 400 
 
Systemic but not topic EPO administration 
stimulates erythropoiesis 
In the present study we administered 
human EPO to pigs using concentrations 
usually applied for treatment of anaemic 
patients. In order to analyze whether the 
human EPO regimen is also functional in 
pigs we analyzed CD117 expression in 
bone marrow cells and determined the ra-
tios between erythropoiesis and myelopoi-
esis at day 14 after surgery. Mean ratios of 
erythropoiesis to myelopoiesis were 0.42 ± 
0.15, 0.47 ± 0.18 and 1.64 ± 0.14 in groups 
1, 2, and 3, respectively (Fig. 5). The dif-
ferences between group 1 and group 3 
(p=0.0043) as well as between group 2 and 
group 3 (p=0.0043) were significant. Thus, 
systemic administration of human EPO 
leads to a stimulation of erythropoiesis also 
in pigs. As expected the topical administra-
tion of EPO in the fibrin sealant did not 
induce erythropoiesis in the bone marrow. 
 
 group 1              group 2               group 3
qu
ot
ie
nt
 e
ry
th
ro
po
ie
si
s/
m
ye
ol
op
oi
es
is
C
D
 1
17
 p
os
.c
el
ls
0,2
0,4
0,6
0,8
1,2
1,4
1,6
1,8
0,0
1,0
2,0 *
 
Figure 5: CD 117 staining of bone marrow on 
day 14 after liver resection. Systemic EPO ad-
ministration (group 3) leads to a significant in-
crease in the ratio of erythropoiesis/myelopoie-
sis (p=0.0043*).  
 
The mean blood hemoglobin (Hb) level 
was 6.37 ± 0.44 mmol/l before surgery. Six 
hours after hepatectomy Hb decreased be-
cause of blood loss, resulting in haemoglo-
bin levels of 5.10 ± 0.14, 4.95 ± 0.64 and 
5.80 ± 0.14 mmol/l in groups 1-3, respec-
tively. One day after hepatectomy Hb levels 
were 5.05 ± 0.34 (group 1), 5.9 ± 0.56 
(group 2) and 5.92 ± 0.60 (group 3) mmol/l 
and increased to 6.01 ± 0.66 (group 1), 6.55 
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± 0.89 (group 2) and 6.6 ± 0.55 (group 3) 
mmol/l 14 days after surgery. Surgery and 
EPO administration did not significantly 
influence hematocrit levels. Prior to liver 
resection, the mean blood hematocrit level 
was 0.32 ± 0.05. Six hours after surgery the 
mean hematocrit levels were 0.30 ± 0.03 
(group 1), 0.32 ± 0.05 (group 2) and 0.36 ± 
0.04 (group 3). At day 14 after surgery the 
respective levels were 0.36 ± 1.10 (group 
1), 0.39 ± 0.06 (group 2) and 0.40 ± 0.02 
(group 3) (Fig. 6). 
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Figure 6: Effect of EPO on hemoglobin levels 
and on the hematocrit after left lateral sided 
liver resection. The slight increase in hemoglo-
bin and hematocrit in group 3 did not reach 
statistical significance.  
 
 
DISCUSSION 
 
Liver regeneration after hepatectomy:  
a need for supportive therapy 
Despite of the progress in understanding 
the molecular mechanisms underlying liver 
regeneration (Michalopoulos and 
DeFrances, 1997, 2005; Gebhardt et al., 
2003), the clinically relevant limits of the 
ability of the liver to regenerate are not well 
understood, and there has been little pro-
gress in the development of therapy to en-
hance regeneration and optimize survival 
when the residual liver after hepatectomy is 
excessively small (Cataldegirmen et al., 
2005). Human liver regeneration is of par-
ticular importance in patients who have 
undergone partial hepatectomy, to patients 
suffering from fulminant hepatic failure, 
and to liver transplant recipients. Although 
the liver has a remarkable regenerative ca-
pacity (Kountouras et al., 2001) it neverthe-
less is often insufficient (Cataldegirmen et 
al., 2005). In particular, hepatic failure can 
occur following therapeutic liver resection. 
Postoperative hepatic insufficiency in a 
large study by Jarnagin et al. occurred in 
approximately 5 % (Jarnagin et al., 2002). 
Therefore, agents improving liver regenera-
tion after hepatectomy would be of consid-
erable benefit for patients. Promising can-
didates include interleukin 6 (IL-6) and 
hepatocyte growth factor (HGR) (Borowiak 
et al. 2004). IL-6 administration in male 
Wistar rats increases liver weight exempli-
fied by positive immunostaining for PCNA 
(Ohira et al., 1996). The designer cytokine, 
Hyper-IL-6, consisting of the soluble IL-6 
receptor covalently linked to IL-6 which 
directly stimulates gp130 and activates in-
tracellular signalling, has been shown to 
improve liver regeneration after partial 
hepatectomy in mice (Peters et al., 2000). 
Previous studies of HGF supplementation 
in liver resection models in rats have led to 
a higher proliferation rate (Ishii et al., 
1995). However, despite promising data in 
the field of conceptual research, neither Il-6 
or HGF can be applied in clinical studies in 
the near future, due to their high cost and 
low availability (Giordano et al., 1993). 
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Many other factors have been shown to be 
relevant in liver regeneration 
(Michalopoulos and DeFrances, 2005) in-
cluding HB-EGF, norepinephrine, am-
phiregulin and TGF-α, but these factors are 
also many years away from being clinically 
relevant. At a first glance erythropoietin 
(EPO) would not be considered to be a first 
line candidate in this field, especially since 
the adult liver has been reported to express 
only very low levels of the EPO receptor 
(Liu et al., 1997; Masuda et al. 1992). How-
ever, the observations discussed below sug-
gest that EPO nevertheless represents a 
promising candidate for preclinical and 
clinical studies on liver regeneration. 
 
EPO in tissue regeneration: systemic ver-
sus cell type specific mechanisms 
The primary action of EPO is to prevent 
the programmed cell death of erythrocytic 
progenitors and to stimulate their growth 
and maturation to normoblasts. The action 
of EPO is induced through its binding to the 
homodimeric EPO receptor, which is a 
member of the cytokine class I receptor 
superfamily (Sawyer, 1989; Swameye et 
al., 2003). After EPO binding, the two re-
ceptor subunits undergo a conformational 
change resulting in the phosphorylation of 
tyrosine residues of two Janus kinase 2 
(JAK2) molecules and the receptors them-
selves (Remy et al., 1999). EPO receptor 
signaling involves the expression of the 
anti-apoptotic protein bcl-xL (Gregory et al., 
1999), the activation of various protein 
kinases and the homodimerization of the 
signal transducer and activator of transcrip-
tion 5 (STAT5) (Oda and Sawada, 2000; 
Yoshimura and Misawa, 1998). Recombi-
nant human EPO is used therapeutically to 
stimulate production, differentiation and 
maturation of erythroid progenitors in pa-
tients with chronic renal failure or those on 
dialysis (Buemi et al., 2002). The admini-
stration of EPO to liver resection patients 
was first reported in 1994 (Kajikawa et al. 
1994) and its purpose was to reduce the 
need for excessive donor blood since do-
nated blood may have adverse effects on 
the immune system. This study demon-
strated a swifter decrease in serum bilirubin 
levels (indicating a return to normal) fol-
lowing postoperative EPO treatment as well 
as a reduction in postoperative complica-
tions. A second trial (Shinozuka et al., 
2000) in which EPO was administrated 
preoperatively to liver resection patients to 
stimulate erythropoiesis, similarly demon-
strated that patients given EPO experienced 
a significant reduction in postoperative 
complications compared to the control 
group. Both studies concentrated on the 
systemic effects of EPO, especially to avoid 
the need for donor blood, and did not dis-
cuss a possible direct influence of EPO on 
liver regeneration.  
Meanwhile, knowledge has improved 
about the physiological functions of EPO 
beyond the classical stimulating effect on 
erythropoiesis: a survey of rat organs has 
revealed hypoxia-inducible expression of 
EPO mRNA in testis, brain, liver and kid-
ney (Tan et al., 1992). EPO enhances the 
maturation of oligodendrocytes and the 
proliferation of astrocytes (Sugawa et al., 
2002). In cardiomyoblasts expression of 
EPO receptors and EPO binding stimulate 
cell proliferation and repress cell differen-
tiation (Ogilvie et al., 2000). EPO receptors 
were identified on human hepatoma cells of 
the line Hep 3B (Ohigashi et al., 1996). 
Recently, expression and signaling through 
the EPO receptor has been demonstrated in 
a variety of non-hematopoietic organs, in-
cluding the brain (neurons and glia), car-
diovascular tissues (endothelium, vascular 
smooth muscle, cardiomyocytes), gastroin-
testinal tissues, pancreatic islands, the kid-
ney, the testis and female reproductive or-
gans (Juul, 2000; Moritz et al., 1997; Sasaki 
et al., 2000; Adamson and Ludwig, 1999). 
Clearly, EPO is a more pleiotropic survival 
and growth factor than earlier thought. In 
particular, the neurotrophic and neuropro-
tective effects of EPO have been docu-
mented in detail (Cerami et al., 2002; 
Chong et al., 2003; Marti et al., 2000; Ma-
suda et al., 1999). Recently, recombinant 
human EPO has been administered success-
fully to patients with acute stroke for reduc-
tion of brain infarct size (Ehrenreich et al., 
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2002). With respect to the effects of EPO in 
the vascular system, the growth factor in-
duces a pro-angiogenic phenotype of endo-
thelial cells and neo-vascularization (Jaquet 
et al., 2002; Carlini et al., 1995). Further-
more, EPO promotes blood vessel forma-
tion in the uterus of ovariectomized mice 
(Yasuda et al., 1998). The signaling path-
ways in neuronal cells (Chong et al., 2003) 
and in vascular cells (Fodinger et al., 2000; 
Haller et al., 1996) involve the activation of 
kinases and transcription factors as in eryth-
rocytic cells.  
 
Topical versus systemic administration of 
EPO to pigs after hepatectomy 
Liver regeneration has been investigated 
mostly in rats or in vitro with hepatocyte 
cultures. Because of the anatomical and 
physiological similarities between human 
and porcine livers, pig liver resection and 
transplantation models have been the back-
bone of experimental surgical research in 
this field (Swindle, 1984; Swindle et al., 
1988; Court et al., 2003). Unfortunately, 
porcine EPO was not available for our stud-
ies. Therefore, human EPO was used be-
cause of its ample availability. Previous 
studies have already described positive ef-
fects of human EPO in pigs (Romsi et al., 
2002; Vogel et al., 1997), and Wen et al. 
(1993) have demonstrated that human and 
pig EPO share 82 % amino acid identity. 
For the EPO dosage, we used a concentra-
tion close to the upper limit recommended 
for the treatment of tumor-related anemia in 
human patients (Adamson and Ludwig, 
1999). Analysis of CD 117 antibody, a 
marker for hematopoetic stem cells found 
in pig bone marrow, demonstrated a signifi-
cant increase following systemic admini-
stration of EPO in our study. Erythropoiesis 
was stimulated in the bone marrow after 
systemic administration of EPO (group 3), 
suggesting that human EPO is functional in 
pigs under our study conditions. 
Combined topical and systemic admini-
stration of EPO led to a 26 % increase in 
liver weight 14 days after hepatectomy. The 
accelerated weight gain was accompanied 
by a 2.8-fold increase in proliferating hepa-
tocytes. In contrast, topical EPO application 
alone had no significant effect on liver 
weight, but also increased hepatocyte pro-
liferation close to the resection surface of 
the left liver lobe, where EPO had been 
topically administered in the fibrin sealant. 
The latter result suggests a direct influence 
of EPO on the liver, since under our study 
conditions topical EPO administration was 
not associated with systemic effects such as 
erythropoiesis in the bone marrow. Clearly 
combined systemic and topical administra-
tion of EPO was much more efficient and 
should be used in further clinical studies. 
The EPO induced increase in hepatocyte 
proliferation was plainly detectable using 
an antibody against Ki-67. In contrast, im-
munostaining for PCNA did not result in a 
significant difference between EPO ex-
posed pigs and controls. This discrepancy 
was not unexpected. Ki-67 immunostaining 
is a well accepted marker specific for cell 
proliferation that has been demonstrated to 
correlate well with BrdU incorporation 
(Muskhelishvili et al., 2003). In contrast, a 
correlation between PCNA expression and 
proliferation, as evidenced by BrdU incor-
poration, has not consistently been ob-
served, since PCNA is also involved in 
other processes than proliferation, such as 
stress response and DNA-repair 
(Muskhelishvili et al., 2003; Zou et al., 
2003). 
Activation of anti-apoptotic or prolifera-
tive signal transduction pathways by EPO 
seems to be improbable since adult hepato-
cytes express no or very low levels of the 
EPO receptor (Masuda et al., 1992). Alter-
natively EPO may be inducing angiogenesis 
in the regenerating liver. EPO has been 
shown to have a role in promoting angio-
genesis, acting as a survival factor for endo-
thelial cells as well as increasing the 
amount of circulating progenitor endothe-
lial cells (Heeschen et al., 2003). More re-
cent publications related to the angiogenic 
potential of EPO further describe the indi-
rect role for EPO in liver regeneration. 
Among these publications are two which 
use animal models to illustrate the role of 
angiogenic factors and endothelial cells in 
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the regeneration of liver. A 2003 Science 
publication (LeCouter et al., 2003) reported 
that following liver damage, hepatocytes 
were shown to secrete VEGF-A which 
stimulated liver endothelium to proliferate 
and in turn release IL-6 and HGF. A second 
publication (Greene et al., 2003) confirms 
that the stimulation of endothelial prolifera-
tion and migration through fibroblast 
growth factor significantly increases the 
rate of regeneration of resected liver while 
an inhibitor of endothelial cells likewise 
stunts liver regeneration. These data indi-
cate an indirect effect of EPO through an-
giogenic mechanisms, whereas our study 
suggests also a direct effect on hepatocytes. 
In our experiments we compared EPO me-
diated phosphorylation of Akt/PKB in 
hepatocytes co-cultured with non-
parenchymal liver cells to hepatocyte 
mono-cultures and did not observe a rele-
vant difference. Therefore, phosphorylation 
of Akt/PKB seems to be independent from 
the non-parenchymal liver cells. Of course 
this does not exclude that other EPO medi-
ated effects on hepatocytes could be medi-
ated by endothelial or other types of non-
parenchymal liver cells. Both indirect and 
direct effects may synergize to result in the 
observed accelerated regeneration.  
 
Erythropoietin: a first line candidate for 
clinical studies in liver regeneration 
Combined systemic and topical admini-
stration of EPO caused a 26 % increase in 
liver weight 14 days after hepatectomy, 
which corresponds to more than 300 g of 
additional liver tissue in the EPO treated 
compared to the control group. Should EPO 
induce a similar improvement of liver re-
generation also in humans a reduction of 
frequency as well as severity of complica-
tions after liver resection can be expected. 
Particularly, the risk of hepatic failure oc-
curring after liver resection will be reduced 
if regeneration of the residual liver is im-
proved. Therefore, we have initiated a dou-
ble-blind, randomized, placebo-controlled, 
monocentre clinical trial in patients treated 
post-operatively with erythropoietin, moni-
toring regeneration rates in patients under-
going liver resection. 
Acknowledgment: The study was sup-
ported by the German Federal Ministry of 
Education and Research (network: Systems 
Biology of the Hepatocyte). 
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